Ibuzatrelvir is an oral antiviral medication being studied for treating COVID-19. It is designed to help people who have COVID-19 but are not hospitalized and are at high risk of their illness becoming more severe. The medication works by targeting the virus that causes COVID-19, aiming to reduce the severity of the infection and prevent the disease from progressing to a more serious state.

COVID-19 – A respiratory disease caused by the SARS-CoV-2 virus that primarily affects the lungs and respiratory system. The infection typically begins with symptoms such as fever, cough, fatigue, and loss of taste or smell. In some cases, the disease can progress from mild to more severe symptoms, particularly in individuals with certain risk factors. The condition can affect multiple body systems and may lead to varying degrees of respiratory difficulties. Some people may develop longer-lasting symptoms known as Long COVID, where effects persist beyond the initial infection period.

Long COVID – A condition where symptoms persist or develop after the initial COVID-19 infection has resolved. Symptoms can include ongoing fatigue, shortness of breath, cognitive difficulties (often called “brain fog”), muscle weakness, and various other physical and neurological effects. The condition can affect daily activities and may fluctuate in intensity over time. Long COVID can occur even in people who had mild initial COVID-19 symptoms.